Promising drug may reduce eye bulging in thyroid disease

NCT ID NCT06106828

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. The goal is to find a safer, non-surgical treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE

Contacts and locations

Locations

AIBILI - Association for Innovation and Biomedical Research on Light

Coimbra, 3000-548, Portugal
Beijing Hospital of Ministry of Health

Beijing, 100730, China
Beijing Tongren Hospital, Capital Medical University

Beijing, 100730, China
Bristol Eye Hospital

Bristol, BS1 2LX, United Kingdom
CHNO Hopital des Quinze Vingts

Paris, 75012, France
CHU Nantes - Hotel Dieu

Nantes, 44093, France
Chung-Ang University Hospital

Seoul, 06973, South Korea
Connecticut Eye Consultants, P.C.

Danbury, Connecticut, 06810, United States
Fondation Rothschild

Paris, 75019, France
Gartnavel General Hospital

Glasgow, G12 0YN, United Kingdom
Hadassah MC

Jerusalem, 9112001, Israel
Hospital Ramon y Cajal

Madrid, 28031, Spain
Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, 8907, Spain
Hospital Universitario Clínico San Carlos

Madrid, 28040, Spain
Hospital Universitario Vall d Hebron

Barcelona, 08035, Spain
Hospital Universitario Virgen de la Macarena

Seville, 41007, Spain
Hospital Universitario Virgen de las Nieves

Granada, 18012, Spain
Hospital Universitario la Fe: Servicio de Oftalmologia

Valencia, 46026, Spain
Maidstone Hospital

Maidstone, Kent, ME16 9QQ, United Kingdom
Moorfields Eye Hospital NHS Foundation Trust

London, EC1V 2PD, United Kingdom
Peking Union Medical College Hospital

Beijing, 100032, China
Peking University Third Hospital

Beijing, 100191, China
Plastics-Orbit-Neuro

San Diego, California, 92108, United States
Profesorskie Centrum Medyczne Spolka Z Ograniczona Odpowiedzialnoscia

Gdansk, 80-180, Poland
Rabin MC

Petah Tikva, 4941492, Israel
Retina Consultants of Texas

San Antonio, Texas, 78251, United States
Royal Liverpool University Hospital

Liverpool, L7 8XP, United Kingdom
Samsung Medical Center

Seoul, 135-710, South Korea
Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States
Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 003-722, South Korea
Sheba medical center

Ramat Gan, Israel
Specjalistyczny Osrodek Okulistyczny Oculomedica

Bydgoszcz, 85-316, Poland
St James University Hospital

Leeds, LS9 7TF, United Kingdom
Sussex Eye Hospital

Brighton, BN2 5BF, United Kingdom
Toronto Retina Institute

Toronto, Ontario, M3C 0G9, Canada
Universite de Montreal - Hopital Maisonneuve-Rosemont

Montreal, Quebec, H1T 2M4, Canada
University of Alberta

Edmonton, Alberta, Canada
University of Illinois Eye and Ear Infirmary

Chicago, Illinois, 60612, United States
Vanderbilt Eye Institute

Nashville, Tennessee, 37232-8808, United States
Xi'an Fourth Hospital

Xi'an, 710004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.